Pernix Therapeutics Announces Restructuring, Integration of Pernix, Hawthorn Sales Forces
Pernix Therapeutics Holdings, Inc. (“Pernix” or the “Company”) (NYSE: PTX), a specialty pharmaceutical company, today announced that the Company has initiated the integration of its Pernix and Hawthorn sales forces. The Company has restructured the combined sales force, reducing the number of sales representatives to approximately 125 from 187. The sales force will remain focused on Pediatrics, Primary Care and Gastroenterology.
The Company today also announced that David Becker will resign his position as Chief Financial Officer, due to personal reasons, effective March 31, 2013. The Company has started a search to identify a new Chief Financial Officer. Upon naming a successor, Mr. Becker will serve the Company as a consultant in several areas, including manufacturing, over-the-counter products, and business development.
© 2015 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.